Skip to main content
[Preprint]. 2022 Nov 29:2022.11.29.518385. [Version 1] doi: 10.1101/2022.11.29.518385

Figure 2: SARS-CoV-2-specific IgG antibody titers in breastmilk correlate with those in maternal circulation.

Figure 2:

(A) RBD-specific IgG levels in breastmilk after the first and second vaccine doses (n=179). (B) IgG isotype levels in breastmilk 174.33 ± 10.08 days after the first and second vaccine doses, (IgG1, n=26; IgG2, n=22; IgG3, n=24; IgG4, n=22). (C) Breastmilk IgG levels 37.84 ± 3.80 days prior to and 55.32 ± 5.30 days after booster (n=45 pairs). (D) RBD-specific IgG antibodies in breastmilk after maternal booster vaccination (n=123). (E) Levels of RBD specific IgG isotypes in breastmilk 57.50 ± 8.17 days before (n=28) and 117.23 ± 11.32 days after the booster dose (n=44). (F) IgG isotype detection of SARS-CoV-2 RBD specific antibodies in breastmilk 115.10 ± 11.46 days after booster dose (n=43). (G-H) Average IgG titers post-partum in women who had not received the booster dose (G) (Prepreg, n=0; T1, n=15; T2, n=52; T3, n=51; Postpartum, n=39) and (H) who had been boosted (Prepreg, n=26; T1, n=14; T2, n=38; T3, n=21; Postpartum, n=12) classified by trimester of initial vaccination. * indicates a significant difference between the antibody levels at that timepoint when comparing pre- and post-booster (panel G vs H). Data are median values ± SEM. (I) Correlation between RBD-specific IgG levels in breastmilk and maternal plasma post-partum (Delivery, n=24; 6 weeks (6wpp), n=60; 3 months (3mopp), n=59; 6 months (6mopp), n=48; 9 months (9mopp), n=32 and 12 months (12m), n=19). * p < 0.03, ** p < 0.002, *** p < 0.0002, **** p<0.0001.